The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral antithrombotic therapy
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Unnamed facility
Saint-Etienne, France
Composite of All-cause Death, Thrombosis (New and Extended) and Unplanned Amputation
Time frame: During and 30 days after argatroban treatment
All-cause Death
Time frame: During and 30 days after argatroban treatment
Death Related to Heparin-induced Thrombocytopenia (HIT)
Time frame: During and 30 days after argatroban treatment
Number of Patients With Thrombosis (New and Extended)
Time frame: During and 30 days after argatroban treatment
Number of Patients With Unplanned Amputation
Time frame: During and 30 days after argatroban treatment
Number of Patients With Major or Minor Bleeding
Major bleeding is defined as i) overt and associated with a fall in the haemoglobin level 2 g/dl or more, ii) leads to transfusion of 2 units or more, iii) is retroperitoneal, iv) occurs into a major prosthetic joint, or v) in intracranial. Minor bleeding is defined as overt bleeding that does not meet the criteria of major bleeding.
Time frame: During and 30 days after argatroban treatment
Number of Patients With Platelet Count Recovery
Platelet increase of ≥ 100G/L or 50%.
Time frame: Day 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.